Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Amgen Inc., consolidated cash flow statement

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	6,717)	6,552)	5,893)	7,264)	7,842)
Depreciation, amortization and other	4,071)	3,417)	3,398)	3,601)	2,206)
Stock-based compensation expense	431)	401)	341)	330)	308)
Deferred income taxes	(1,273)	(1,198)	(453)	(287)	(289)
Acquired in-process research and development	—)	—)	1,505)	—)	—)
Adjustments for equity method investments	11)	891)	33)	65)	—)
Loss on divestiture	—)	567)	—)	—)	—)
(Gains) losses on equity securities	(1,565)	127)	—)	—)	—)
Other items, net	563)	(303)	(262)	(260)	(186)
Trade receivables, net	(1,015)	(746)	(429)	(427)	(504)
Inventories	491)	(742)	(165)	(215)	(66)
Other assets	(564)	258)	(237)	129)	10)
Accounts payable	(402)	154)	(69)	45)	164)
Accrued income taxes, net	(1,031)	(647)	(854)	(249)	(585)
Long-term tax liabilities	371)	229)	204)	(482)	(146)
Accrued sales incentives and allowance	935)	846)	404)	—)	—)
Other liabilities	731)	(85)	(48)	983)	396)
Changes in operating assets and liabilities, net of acquisitions	(484)	(733)	(1,194)	(216)	(731)
Net cash provided by operating activities	8,471)	9,721)	9,261)	10,497)	9,150)
Cash paid for acquisitions, net of cash acquired	(26,989)	(3,839)	(2,529)	—)	(13,617)
Purchases of marketable securities	(1)	(2,587)	(8,900)	(8,477)	(9,394)
Proceeds from sales of marketable securities	1,123)	98)	4,403)	2,597)	8,842)
Proceeds from maturities of marketable securities	550)	1,120)	8,831)	4,381)	20,548)
Purchases of property, plant and equipment	(1,112)	(936)	(880)	(608)	(618)
Other	225)	100)	(192)	(3,294)	(52)
Net cash (used in) provided by investing activities	(26,204)	(6,044)	733)	(5,401)	5,709)
Net proceeds from issuance of debt	27,777)	6,919)	4,945)	8,914)	—)
Extinguishment of debt	(647)	(297)	—)	—)	—)
Repayment of debt	(1,454)	—)	(4,150)	(6,450)	(4,514)
Repurchases of common stock	—)	(6,360)	(4,975)	(3,486)	(7,702)
Dividends paid	(4,556)	(4,196)	(4,013)	(3,755)	(3,509)
Other	(72)	(103)	(78)	(90)	(42)
Net cash provided by (used in) financing activities	21,048)	(4,037)	(8,271)	(4,867)	(15,767)
Increase (decrease) in cash and cash equivalents	3,315)	(360)	1,723)	229)	(908)
Cash and cash equivalents at beginning of year	7,629)	7,989)	6,266)	6,037)	6,945)
Cash and cash equivalents at end of year	10,944)	7,629)	7,989)	6,266)	6,037)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Cash flow statement item	Description	The company
Net cash provided by operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	Amgen Inc. net cash provided by operating activities increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Net cash (used in) provided by investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	Amgen Inc. net cash (used in) provided by investing activities decreased from 2021 to 2022 and from 2022 to 2023.
Net cash provided by (used in) financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	Amgen Inc. net cash provided by (used in) financing activities increased from 2021 to 2022 and from 2022 to 2023.

Amgen Inc. (NASDAQ:AMGN)

Cash Flow Statement